SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (92)10/8/1997 1:01:00 AM
From: Miljenko Zuanic   of 579
 
Rick:

Muskarinic receptor agonist seams good target for dementia in Alzhemier's disease. Acetilcholin esterase inhibitors (first and second generation) are known story and there is nothing new.
Chiral 2-Oxo-azabicyclic hepten derivatives are known muskarinic agonist, but with pure selectivity toward sub-group. It appears that SKB developed potent and selective agonist.

Of topic:

In future (Oct. 15) isuue of the "The Journal of Clinican Investigation" the listed article will be printed:

>>P. Lin, P. Polverini, M. Dewhirst, S. Shan, P.S. Rao, and K. Peters
Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic
vascular growth<<

Are the autors known to you?

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News